Clover Biopharmaceuticals raised a $230 million series C round co-led by GL Ventures and Temasek, which will push the Chinese fusion protein company’s Covid-19 vaccine into Phase II/III testing and production planning.

Johnson & Johnson expects to be able to ship nearly 4 million doses of the company’s Covid-19 vaccine upon authorization in the U.S., an executive said at a hearing in the U.S. House of Representatives on Feb. 23.

Public Health England (PHE) published real-world analyses of people in the U.K. who had received the first shot of the Pfizer-BioNTech Covid-19 vaccine, with the data – which were published in The Lancet – showing that there was a decrease of about 70 percent in infections among healthcare workers after the first shot.

The U.S. Food and Drug Administration issued new guidance for vaccine makers as the regulatory agency is preparing for the possibility of needing to approve Covid-19 booster shots against variants of the SARS-CoV-2 virus.

FDA to allow Pfizer-BioNTech vaccine to be stored at higher temps: NYT (Reuters) – The U.S. Food & Drug Administration plans to approve Pfizer Inc and BioNTech SE’s request to store their COVID-19 vaccine at standard freezer temperatures instead of in ultra-cold conditions, the New York Times reported on Tuesday. The FDA is expected to […]

Drugmakers should test any Covid-19 vaccines that have been retooled to combat new variants of the coronavirus in clinical trials designed to track the immune response of hundreds of subjects, which could take months, U.S. regulators said on Feb. 22.

Drug developer Novavax Inc. completed enrolling 30,000 volunteers in a late-stage study of the company’s Covid-19 vaccine in the United States and Mexico.

U.S. President Joe Biden secured a commitment from Pfizer Inc. to double the Covid-19 vaccine the company churns out in the coming weeks, putting his goal to fill the country’s inoculation stockpile by summer in sight.

Novavax announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to provide 1.1 billion doses of the company’s Covid-19 vaccine candidate NVX-CoV2373 for the COVAX Facility.

The two Covid-19 vaccines approved for use in the United States have reassuring safety profiles, the U.S. Centers for Disease Control and Prevention said on Feb. 19 after monitoring the first month of vaccinations between December 2020 and January 2021.